Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Ren, ZhenggangZhenggangRenDucreux, MichelMichelDucreuxAbou-Alfa, Ghassan KGhassan KAbou-AlfaMerle, PhilippePhilippeMerleFang, WeijiaWeijiaFangEdeline, JulienJulienEdelineLi, ZhiweiZhiweiLiWu, LihuaLihuaWuAssenat, EricEricAssenatHu, ShengShengHuRimassa, LorenzaLorenzaRimassaZhang, TaoTaoZhangBlanc, Jean-FrédéricJean-FrédéricBlancPan, HongmingHongmingPanRoss, PaulPaulRossYen, Chia-JuiChia-JuiYenTran, AlbertAlbertTranShao, GuoliangGuoliangShaoBouattour, MohamedMohamedBouattourChen, YajinYajinChenMeyer, TimTimMeyerHou, JinlinJinlinHouTougeron, DavidDavidTougeronBai, YuxianYuxianBaiHou, Ming-MoMing-MoHouMeng, ZhiqiangZhiqiangMengWu, JohnJohnWuLi, VincentVincentLiChica-Duque, SandraSandraChica-DuqueANN-LII CHENG2023-05-102023-05-102023-022235-1795https://scholars.lib.ntu.edu.tw/handle/123456789/630967Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC.enHepatocellular carcinoma; Immunotherapy; Pretreated patient population; Tislelizumab[SDGs]SDG3Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trialjournal article10.1159/000527175368729272-s2.0-85149114581WOS:000891685000001https://api.elsevier.com/content/abstract/scopus_id/85149114581